Northwest Biotherapeutics (STU:NBYB) Cyclically Adjusted FCF per Share: €-0.11 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:NBYB Northwest Biotherapeutics Inc STU:NBYB
17 GF Score
Price €0.15
GF Value €0.24
Valuation Possible Value Trap
! 5 Warning Signs
View Full Analysis

What is Northwest Biotherapeutics Cyclically Adjusted FCF per Share?

Northwest Biotherapeutics STU:NBYB 17 Cyclically Adjusted FCF per Share is €-0.11 as of Mar. 2026. GuruFocus rates STU:NBYB with a GF Score™ of 17/100 and a GF Value™ of €0.24 (Possible Value Trap). The stock has 5 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

Northwest Biotherapeutics's adjusted free cash flow per share for the three months ended in Mar. 2026 was €-0.007. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is €-0.11 for the trailing ten years ended in Mar. 2026.

During the past 3 years, the average Cyclically Adjusted FCF Growth Rate was 33.90% per year. During the past 5 years, the average Cyclically Adjusted FCF Growth Rate was 28.30% per year. During the past 10 years, the average Cyclically Adjusted FCF Growth Rate was 27.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted FCF Growth Rate of Northwest Biotherapeutics was 46.60% per year. The lowest was 18.10% per year. And the median was 31.90% per year.

As of today (2026-07-30), Northwest Biotherapeutics's current stock price is €0.15. Northwest Biotherapeutics's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2026 was €-0.11. Northwest Biotherapeutics's Cyclically Adjusted Price-to-FCF of today is .


Northwest Biotherapeutics  (STU:NBYB) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


Northwest Biotherapeutics Cyclically Adjusted FCF per Share Related Terms


Northwest Biotherapeutics Cyclically Adjusted FCF per Share Historical Data

* Premium members only.

The historical data trend for Northwest Biotherapeutics's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Northwest Biotherapeutics Cyclically Adjusted FCF per Share Chart

Northwest Biotherapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.55 -0.48 -0.35 -0.31 -0.14

Northwest Biotherapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.24 -0.16 -0.16 -0.14 -0.11

STU:NBYB vs FATE, IMRX, FHTX: Cyclically Adjusted FCF per Share Comparison

For the Biotechnology subindustry, Northwest Biotherapeutics's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Northwest Biotherapeutics Cyclically Adjusted Price-to-FCF vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Northwest Biotherapeutics's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Northwest Biotherapeutics's Cyclically Adjusted Price-to-FCF falls into.


STU:NBYB
17GF Score
Northwest Biotherapeutics Inc STU:NBYB
Cyclically Adjusted FCF per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Northwest Biotherapeutics Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Northwest Biotherapeutics's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2026 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=-0.007/330.2130*330.2130
=-0.007

Current CPI (Mar. 2026) = 330.2130.

Northwest Biotherapeutics Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201606 -0.136 241.018 -0.186
201609 -0.079 241.428 -0.108
201612 -0.106 241.432 -0.145
201703 -0.071 243.801 -0.096
201706 -0.016 244.955 -0.022
201709 -0.017 246.819 -0.023
201712 -0.039 246.524 -0.052
201803 -0.011 249.554 -0.015
201806 -0.023 251.989 -0.030
201809 -0.007 252.439 -0.009
201812 -0.024 251.233 -0.032
201903 -0.017 254.202 -0.022
201906 -0.014 256.143 -0.018
201909 -0.010 256.759 -0.013
201912 -0.009 256.974 -0.012
202003 -0.011 258.115 -0.014
202006 -0.010 257.797 -0.013
202009 -0.012 260.280 -0.015
202012 -0.013 260.474 -0.016
202103 -0.014 264.877 -0.017
202106 -0.006 271.696 -0.007
202109 -0.007 274.310 -0.008
202112 -0.012 278.802 -0.014
202203 -0.012 287.504 -0.014
202206 -0.014 296.311 -0.016
202209 -0.016 296.808 -0.018
202212 -0.010 296.797 -0.011
202303 -0.011 301.836 -0.012
202306 -0.011 305.109 -0.012
202309 -0.012 307.789 -0.013
202312 -0.014 306.746 -0.015
202403 -0.010 312.332 -0.011
202406 -0.013 314.175 -0.014
202409 -0.006 315.301 -0.006
202412 -0.015 315.605 -0.016
202503 -0.006 319.799 -0.006
202506 -0.004 322.561 -0.004
202509 -0.008 324.800 -0.008
202512 -0.009 324.054 -0.009
202603 -0.007 330.213 -0.007

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

What does a Cyclically Adjusted FCF per Share of €-0.11 mean?
Northwest Biotherapeutics (STU:NBYB) has a Cyclically Adjusted FCF per Share of €-0.11 as of Mar. 2026. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Northwest Biotherapeutics and its competitors.
Is Northwest Biotherapeutics' Cyclically Adjusted FCF per Share too high?
Northwest Biotherapeutics' current Cyclically Adjusted FCF per Share is €-0.11. Overall, Northwest Biotherapeutics has a GF Score™ of 17/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Northwest Biotherapeutics' Cyclically Adjusted FCF per Share compare to FATE and IMRX?
Northwest Biotherapeutics' Cyclically Adjusted FCF per Share of €-0.11 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted FCF per Share for a Biotechnology company?
A good Cyclically Adjusted FCF per Share depends on the Biotechnology industry context. However, Cyclically Adjusted FCF per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted FCF per Share mean?
A high Cyclically Adjusted FCF per Share can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Northwest Biotherapeutics and its competitors. Northwest Biotherapeutics's current Cyclically Adjusted FCF per Share is €-0.11. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Northwest Biotherapeutics stock overvalued right now?
Based on GuruFocus' analysis, Northwest Biotherapeutics (STU:NBYB) is currently considered Possible Value Trap. The stock's GF Value™ is €0.24, compared to a current price of €0.15 — trading 37.5% below its estimated fair value. The current Cyclically Adjusted FCF per Share is €-0.11. Northwest Biotherapeutics' overall GF Score™ is 17/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted FCF per Share calculated?
Cyclically Adjusted FCF per Share is calculated from a company's financial statements. For Northwest Biotherapeutics (STU:NBYB), the current Cyclically Adjusted FCF per Share is €-0.11 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Northwest Biotherapeutics (STU:NBYB) Overvalued in 2026?

Based on GuruFocus' analysis, Northwest Biotherapeutics stock appears to be undervalued. The current stock price of €0.15 is trading 37.5% below its estimated GF Value™ of €0.24. GuruFocus considers Northwest Biotherapeutics to be Possible Value Trap.

Key valuation signals for STU:NBYB:

  • Cyclically Adjusted FCF per Share: €-0.11
  • GF Value™: €0.24 vs. price of €0.15 (37.5% below fair value)
  • GF Score™: 17/100 with 5 warning signs

No single metric tells the full story. See the STU:NBYB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Northwest Biotherapeutics Business Description

Other Exchanges NWBO:USA
Address 4800 Montgomery Lane, Suite 800, Bethesda, MD, USA, 20814
Northwest Biotherapeutics Inc a biotechnology company focused on developing personalized immune therapies for cancer. The target is a broad range of solid-tumor cancers. The company has a proprietary manufacturing technology, which it uses to produce a personalized vaccine. The product portfolio includes product candidates such as DCVax-L, for patients with brain cancer; DCVax-Direct, direct injection into all types of inoperable solid tumor cancers, and DCVax for late-stage ovarian cancer. DCVax-Prostate, for late-stage prostate cancer, has received clearance from the U.S Food and Drug Administration.
17GF Score

Get the complete analysis for STU:NBYB

Cyclically Adjusted FCF per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.15
Price
€0.24
GF Value